ACM
BIO icon

Arvin Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Arvin Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-18,184
Closed -$5.87M – 30
2023
Q4 		$5.87M Buy
+18,184
New +$5.7M 2.59% 15

Other funds holding BIO

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
VAM
Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
EARNEST Partners
EARNEST Partners Atlanta, Georgia $24.3B AUM 34.41% 1-Year Est. Return
Select Equity Group
Select Equity Group New York $19.5B AUM 17.33% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return
Ninety One (UK)
Ninety One (UK) London, United Kingdom $44.7B AUM 17.24% 1-Year Est. Return

Arvin Capital Management's BIO Position: Q1 2024 in Review

Arvin Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2024, closing a stake of 18,184 shares — an estimated $5.87M sold.

Arvin Capital Management first reported a position in BIO in Q4 2023 and held it in 1 quarter. The position peaked at $5.87M in Q4 2023. 466 funds tracked by Wall St. Rank hold BIO as of Q1 2024.

  • Arvin Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2024 after selling out during the quarter.
  • Arvin Capital Management sold 18,184 Bio-Rad Laboratories Class A shares in Q1 2024, an estimated $5.87M.
  • Arvin Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2023 and held it in 1 quarter.
  • Arvin Capital Management's Bio-Rad Laboratories Class A position peaked at $5.87M in Q4 2023.
  • 466 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2024.

Based on Arvin Capital Management's 13F filing for Q1 2024, filed 14 May 2024.